Infliximab (anti-TNF-alpha)

製品コード：A2019         Batch: A201901

印刷

Infliximab (anti-TNF-alpha) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa.

製品説明

CAS No. 170277-31-3
Formulation PBS, pH 7.0 Contains no stabilizers or preservatives
Isotype Chimeric IgG1
Source Chimeric (mouse/human)
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 97.9%
Protein concentration 5.00mg/ml
Endotoxin Level <1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

An animal model of NLRC4-associated autoinflammation and infantile enterocolitis reveals novel therapeutic strategies [ Cell Mol Immunol, 2025, 10.1038/s41423-025-01355-x] PubMed: 41116055
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies [ Cancer Commun (Lond), 2024, 44(3):408-432] PubMed: 38407943
Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages [ Nat Commun, 2023, 14(1):3902] PubMed: 37400454
Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages [ Nat Commun, 2023, 14(1):3902] PubMed: 37400454
Human iPSC-Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System [ Small, 2023, 19(34):e2203725] PubMed: 37104853
Human iPSC-Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System [ Small, 2023, e2203725.] PubMed: 37104853
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma [ Front Immunol, 2022, 13:854995] PubMed: 35359966

人間や獣医の診断であるか治療的な使用のためにでない。